Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

BTIG Reiterates Buy on Viking Therapeutics, Maintains $125 Price Target

Author: Benzinga Newsdesk | September 22, 2025 10:26am
BTIG analyst Justin Zelin reiterates Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $125 price target.

Posted In: VKTX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist